Markets are Closed
Company Logo
NBIX
Neurocrine Biosciences Inc.

Open

Previous Open

High

98.97

Previous High

Low

94.36

Previous Low

Close

95.33

Previous Close

Volume

924,422

Previous Volume

Company Profile

Description

Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

Exchange

Nasdaq Global Select

List Date

May 23, 1996

CEO

Kevin C. Gorman

Employees

470

Financials

Revenue

788.08M

Earnings

78.50M
496M
340M
184M
28M
-126M
2015
2016
2017
2018

Splits

No splits to date

Dividends

No dividends paid to date

Related News

News post image: Should Neurocrine Biosciences (NASDAQ:NBIX) Be Disappointed With Their 97% Profit?
Should Neurocrine Biosciences (NASDAQ:NBIX) Be Disappointed With Their 97% Profit?
Mar 14, 2020 @ 14:59
While Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shareholders are probably generally happy, the stock hasn't had......
finance yahoo
News post image: Hedge Funds Aren’t Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore
Hedge Funds Aren’t Crazy About Neurocrine Biosciences, Inc. (NBIX) Anymore
Mar 12, 2020 @ 00:53
Coronavirus is probably the 1 concern in investors’ minds right now. It should be. On February 27th we published this article and predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 months. We also told you to short the market ETFs and buy long-term […...
finance yahoo
News post image: Stock Upgrades: Neurocrine Biosciences Shows Rising Relative Strength
Stock Upgrades: Neurocrine Biosciences Shows Rising Relative Strength
Mar 11, 2020 @ 18:45
Neurocrine Biosciences shows improving price performance, earning an upgrade to its IBD Relative Strength Rating...
finance yahoo
News post image: Neurocrine Biosciences Stock Rating Jumps Amid Expanded Use Plans
Neurocrine Biosciences Stock Rating Jumps Amid Expanded Use Plans
Mar 05, 2020 @ 19:38
On Thursday, Neurocrine Biosciences got an upgrade for its IBD SmartSelect Composite Rating from 92 to 96, on a 1-99 scale, with 99 the best possible. Neurocrine Biosciences broke out earlier, but is now around -5% below the prior 101.11 entry from a cup with handle. In the case where a stock breaks out then falls 7% or more below the entry price, it's considered a failed breakout....
finance yahoo
News post image: Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference
Neurocrine Biosciences to Present at Cowen 40th Annual Health Care Conference
Feb 25, 2020 @ 21:01
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Cowen 40th Annual Health Care Conference at 12:00 p.m. Eastern Time on Tuesday, Mar. 3, 2020, in Boston. Kevin Gorman, Chief Executive Officer, will present at the conference....
finance yahoo
News post image: Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club
Neurocrine Biosciences Earns Membership In 95-Plus Composite Rating Club
Feb 19, 2020 @ 17:08
Neurocrine Biosciences saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 94 the day before....
finance yahoo
News post image: Edited Transcript of NBIX earnings conference call or presentation 4-Feb-20 9:30pm GMT
Edited Transcript of NBIX earnings conference call or presentation 4-Feb-20 9:30pm GMT
Feb 15, 2020 @ 12:37
Q4 2019 Neurocrine Biosciences Inc Earnings Call...
finance yahoo
News post image: Earnings Miss: Neurocrine Biosciences, Inc. Missed EPS By 52% And Analysts Are Revising Their Forecasts
Earnings Miss: Neurocrine Biosciences, Inc. Missed EPS By 52% And Analysts Are Revising Their Forecasts
Feb 07, 2020 @ 14:28
Investors in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) had a good week, as its shares rose 2.8% to close at US$103......
finance yahoo
News post image: Can Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Improve Its Returns?
Can Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Improve Its Returns?
Feb 05, 2020 @ 14:35
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is......
finance yahoo
News post image: Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates
Neurocrine Biosciences (NBIX) Q4 Earnings Lag Estimates
Feb 04, 2020 @ 22:55
Neurocrine (NBIX) delivered earnings and revenue surprises of -57.32% and 0.71%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?...
finance yahoo
All data provided on Polygon is provided for informational purposes only, and is not intended for trading or investing purposes.
Copyright © 2021, Polygon.io, Inc. All Rights Reserved.
TradingView Lightweight Chart: Copyright (с) 2020 TradingView, Inc. https://www.tradingview.com/